Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05718557 · ClinicalTrials.gov registry record · Phase 1
Study of PYX-106 in Solid Tumors
A Phase 1 study of Solid Tumor, sponsored by Pyxis Oncology.
- Active
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
- 20
- Study locations
NCT05718557: Active Phase 1 study of Solid Tumor, sponsored by Pyxis Oncology.
NCT05718557 is a Phase 1 study of Solid Tumor that is active but no longer recruiting, run by Pyxis Oncology. The registered enrollment target is 47 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (79% lower). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05718557, a Phase 1 study of Solid Tumor, is active but no longer recruiting, sponsored by Pyxis Oncology.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to determine the recommended dose(s) of PYX-106 in participants with relapsed/refractory solid tumors.
Conditions Studied
Interventions
- DRUG PYX-106
Study Locations (20)
Madrid
- START Madrid - Hospital Universitario Fundación Jiménez Díaz - Madrid
- Hospital Universitario 12 de Octubre - Madrid
- HM Centro Integral Oncológico Clara Campal - Madrid
California
- University of California San Diego - La Jolla
- University of Southern California - Los Angeles
Arizona
- HonorHealth Research Institute - Scottsdale
Colorado
- SCRI- HealthOne Denver - Denver
Georgia
- Winship Cancer Institute of Emory University - Atlanta
Illinois
- University of Chicago Medicine - Chicago
Massachusetts
- Dana-Farber Cancer Institute - Boston
Ohio
- Gabrail Cancer and Research Center - Canton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2023-05-23 |
| Est. Completion | 2026-05 |
| Phase | Phase 1 |
What the registry record for NCT05718557 still lists
NCT05718557 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (79% lower).
The record links to 1 condition, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which PYX-106 is the first listed.
NCT05718557 names 20 study sites across 17 states, led by Madrid, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT05718557 about?
NCT05718557 is a clinical study titled "Study of PYX-106 in Solid Tumors". The primary objective of this study is to determine the recommended dose(s) of PYX-106 in participants with relapsed/refractory solid tumors.
What is the current status of trial NCT05718557?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2023-05-23. Estimated completion is 2026-05.
What conditions does trial NCT05718557 study?
This clinical trial studies the following conditions: Solid Tumor.
What interventions are being tested in trial NCT05718557?
The interventions under investigation include: PYX-106 (DRUG).
Who is sponsoring clinical trial NCT05718557?
This trial is sponsored by Pyxis Oncology, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05718557 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05718557's enrollment target sits among peer trials
47 130th of 196 higher than 67 of 196 other Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI